Ophthalmic Drugs: Advancing Your Ocular Drug Pipeline

02:21 EDT 31 Jul 2017 |

London, United Kingdom, July 31, 2017 --( Do you have questions on novel endpoints in clinical trials? Looking to explore long-term clinical gene expression in patients? Interested in receiving progressive insight into the future of chronic ocular diseases?

SMi Group are delighted to welcome your insights and have you join the discussions at Ophthalmic Drugs 2017, which is being held on the 28th – 29th November 2017 at the Copthorne Tara Hotel in London, UK. Have your say and questions answered during our two pivotal sessions, presented by Oxford BioMedica and NightstaRx.

Day 1: Development of a Lentiviral Vector Platform for the Treatment of Chronic Ocular Disease
Speaker: Scott Ellis, Head of Early Development, Oxford BioMedica.

This presentation will introduce the LentiVector® platform for gene and cell therapy, enable you to experience translating from preclinical studies to First-in-Man clinical trials and explore current challenges and future goals.

Day 1: Novel Endpoints in Ophthalmic Clinical Trials
Speaker: Aniz Girach, Chief Medical Officer, NightstaRx.

Get stuck in with NightstaRx as they examine how you can measure each key endpoint in a certain timescale, explore the pros and cons of these and gain a deeper understanding by hearing from regulators as they provide their feedback on these endpoints.

Check out the full agenda here:

For those looking to attend there is currently a £300 early bird saving, for a limited time only.

Further information is available at:

SMi is Proud to Present the Launch of…
Ophthalmic Drugs
Date: 28th – 29th November 2017
Location: London, UK



Contact Information:

For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email:

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at

Contact Information:
SMi Group
Pav Solanki
+44 (0) 207 827 6048
Contact via Email

Read the full story here:

Press Release Distributed by

Original Article: Ophthalmic Drugs: Advancing Your Ocular Drug Pipeline


More From BioPortfolio on "Ophthalmic Drugs: Advancing Your Ocular Drug Pipeline"

Quick Search

Relevant Topics

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...

Gene Expression
The process of gene expression is used by eukaryotes, prokaryotes, and viruses to generate the macromolecular machinery for life. Steps in the gene expression process may be modulated, including the transcription, RNA splicing, translation, and post-tran...

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...